TGFBR2 and breast cancer: In contrast, silencing ALK4 increased the levels of both glycosylated and non-glycosylated TβRII in pancreatic and breast cancer models and enhanced resistance to endoglycosidase H (EndoH) (Fig. 5g), supporting preferential accumulation of glycosylated TβRII.